Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

Amneal and mAbxience currently partner on ALYMSYS ®, a bevacizumab biosimilar, which was launched in 2022. “Amneal is building its position in the U.S. biosimilars market as this next wave of ...

Dr. Reddy’s has expanded its biosimilars facility in India to meet growing demand in emerging markets. In the fourth quarter of fiscal 2024, the company launched Versavo (bevacizumab), a ...

HERCESSI in the U.S., Zercepac in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Biocon Biologics Ltd on Monday announced that it has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new multi-product monoclonal antibodies ...

Avastin (bevacizumab) is a prescription drug used to treat certain types of cancer. Avastin is also available as a biosimilar drug. It’s prescribed for adults ages 18 years and older.